AdvanSix | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 410.02 M

LB filings
2025.08.01 20:12
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 410.02 M, missing the estimate of USD 431.8 M.

EPS: As of FY2025 Q2, the actual value is USD 1.15, beating the estimate of USD 1.11.

EBIT: As of FY2025 Q2, the actual value is USD 31.65 M, missing the estimate of USD 41.7 M.

Segment Revenue

  • Nylon: $79.5 million for the three months ended June 30, 2025, representing 20% of total sales, compared to $103.2 million for the same period in 2024, representing 23% of total sales. For the six months ended June 30, 2025, revenue was $167.9 million, representing 21% of total sales, compared to $187.6 million in 2024, representing 24% of total sales.
  • Caprolactam: $66.4 million for the three months ended June 30, 2025, representing 16% of total sales, compared to $81.3 million in 2024, representing 18% of total sales. For the six months ended June 30, 2025, revenue was $133.9 million, representing 17% of total sales, compared to $142.8 million in 2024, representing 18% of total sales.
  • Plant Nutrients: $156.8 million for the three months ended June 30, 2025, representing 38% of total sales, compared to $147.3 million in 2024, representing 32% of total sales. For the six months ended June 30, 2025, revenue was $285.0 million, representing 36% of total sales, compared to $242.0 million in 2024, representing 30% of total sales.
  • Chemical Intermediates: $107.3 million for the three months ended June 30, 2025, representing 26% of total sales, compared to $121.6 million in 2024, representing 27% of total sales. For the six months ended June 30, 2025, revenue was $201.1 million, representing 26% of total sales, compared to $217.9 million in 2024, representing 28% of total sales.

Operational Metrics

  • Net Income: $31.4 million for the three months ended June 30, 2025, compared to $38.9 million in 2024. For the six months ended June 30, 2025, net income was $54.7 million, compared to $21.5 million in 2024.
  • Gross Margin: 14.3% for the three months ended June 30, 2025, compared to 17.9% in 2024. For the six months ended June 30, 2025, gross margin was 14.2%, compared to 10.7% in 2024.
  • Operating Costs: Costs of goods sold were $351.3 million for the three months ended June 30, 2025, compared to $372.1 million in 2024. For the six months ended June 30, 2025, costs of goods sold were $675.6 million, compared to $706.0 million in 2024.

Cash Flow

  • Operating Cash Flow: $32.6 million for the six months ended June 30, 2025, compared to $14.0 million in 2024.
  • Free Cash Flow: Not explicitly stated, but net change in cash and cash equivalents was -$1.1 million for the six months ended June 30, 2025, compared to -$17.7 million in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company plans to continue its focus on the SUSTAIN growth program, with capital expenditures expected to be approximately $135 million to $145 million in 2025.
  • Non-Core Business: No specific plans related to divestitures or emerging segments were mentioned in the report.

Outlook Summary

The company anticipates that its future cash from operations, cash on hand, and available capacity under its credit agreement will provide adequate resources to fund its expected operating and financing needs and obligations. The company also expects capital expenditures to be approximately $135 million to $145 million in 2025, reflecting the planned progression of its SUSTAIN growth program.

Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.